Plain-English translation of NCT05441267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 2 research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
ASCEND PLUS is a large research study testing whether oral semaglutide, a medication that helps control blood sugar, can prevent heart attacks and strokes in people with type 2 diabetes. About 20,000 people will participate, and the study uses innovative technology so you can take part mostly from home. The medication or a placebo (dummy pill) will be mailed to you, and your health will be tracked through your existing NHS records.
People with type 2 diabetes face a higher risk of heart attacks and strokes. Researchers want to find out whether this medication, which is already used to help manage blood sugar and weight, can also protect the heart and blood vessels in people who haven't yet experienced these serious events.
You likely qualify if…
You likely don't qualify if…
First, you'll take the medication at increasing doses for 8–12 weeks to see how you tolerate it. If you're then randomly selected for the study, you'll take either the medication at 14mg daily (or a lower 7mg dose if needed) or a placebo for about 5 years. Everything happens at home: your medication is mailed to you, you'll use a secure website or phone/video calls to stay in touch, and your health will be monitored through your NHS records. After the main treatment period ends, researchers will continue tracking your health for up to 20 years through your routine NHS data.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom